Bristol-Myers Squibb Co logo

BMY - Bristol-Myers Squibb Co Share Price

$66.72 -0.1  -0.1%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £120.24bn
Enterprise Value £114.49bn
Revenue £18.58bn
Position in Universe 58th / 6410
Bullish
Bearish
Unlock BMY Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BMY Revenue Unlock BMY Revenue

Net Income

BMY Net Income Unlock BMY Revenue

Normalised EPS

BMY Normalised EPS Unlock BMY Revenue

PE Ratio Range

BMY PE Ratio Range Unlock BMY Revenue

Dividend Yield Range

BMY Dividend Yield Range Unlock BMY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BMY EPS Forecasts Unlock BMY Revenue
Profile Summary

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated August 11, 1933
Public Since July 5, 1929
No. of Shareholders: 39,418
No. of Employees: 23,300
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange New York Stock Exchange
Shares in Issue 2,344,194,343
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BMY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BMY
Upcoming Events for BMY
Similar to BMY
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.